Form 4: Imunon Inc. Executive Chairman Trades Shares

Michael H. Tardugno, Executive Chairman of Imunon, Inc., reported a transaction involving the acquisition of 3,484 shares of common stock on May 22, 2026, at a price of $2.2 per share.

Summary

• Michael H. Tardugno, Executive Chairman and Director of Imunon, Inc., acquired 3,484 shares of common stock on May 22, 2026, for $2.2 per share.
• Following this transaction, Tardugno beneficially owns 8,749 shares of common stock.
• An additional 4,622 shares are held indirectly through a 401(k) plan.
• The filing also notes a 15% stock dividend paid on August 21, 2025, which adjusted previously reported share amounts.
• The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c) affirmative defense conditions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a routine insider transaction under a pre-arranged plan, without providing new operational or financial information.

Positives

• Executive Chairman acquired shares, indicating potential confidence in the company.
• The acquisition was made at a price of $2.2 per share.
• The transaction was executed under a Rule 10b5-1(c) plan, suggesting pre-planned trading activity.

Negatives

• The filing does not provide details on the total value of the transaction beyond the per-share price and quantity.

Risks

• No specific risks were detailed in this Form 4 filing.

Future Outlook

No forward-looking statements or guidance were provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and do not inherently signal significant strategic shifts. The use of a Rule 10b5-1(c) plan indicates a structured approach to personal trading by management.

Stakeholder Impact

• Shareholders may view the acquisition of shares by the Executive Chairman as a positive signal of confidence, though the transaction was conducted under a pre-planned trading program.

Next Steps

• No specific next steps were detailed in this Form 4 filing.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Imunon Inc., IMNN, Michael H. Tardugno, Common Stock, Beneficial Ownership, Rule 10b5-1(c)